Clinical Trial Update: IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing IMC-A12 (cixutumumab) plus mitotane versus mitotane alone in recurrent, metastatic, or unresectable adrenocortical carcinoma was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• IMC-A12 (cixutumumab)
• LYSODREN (MITOTANE)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2013-11-06